Drug Trial Radar · NCT07630155
Office-Based Ureteroscopy Utilizing a Single Use Digital, Flexible Ureteroscope for Upper Tract Urothelial Carcinoma
Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
10
Planned (sponsor's estimate)
Start
Oct 26, 2026
Primary completion
Oct 2027
Study completion Oct 2027
Sponsor
- Lead sponsor
- University of Michigan Rogel Cancer CenterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Shenzhen HugeMed Medical Technical Development
- First posted
- Jun 5, 2026
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Diagnostic
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This clinical trial tests how well office based ureteroscopy utilizing a single use digital, flexible ureteroscope works for the assessment of upper tract urothelial carcinoma. Ureteroscopy is a procedure in which a thin camera called a ureteroscope is used to assess patients with a known or suspected diagnosis of upper tract urothelial carcinoma. Ureteroscopy is traditionally performed in an operating room under general anesthesia. In this study, patients undergo ureteroscopy in the doctor's office using an ultra-thin ureteroscope, which is the narrowest instrument of its kind. Because of its small size, researchers believe this procedure can be completed in the office with minimal discomfort and high patient satisfaction, which may eliminate the risks of general anesthesia and reduce delays to diagnosis. Office based ureteroscopy utilizing a single use digital, flexible ureteroscope may be effective for the assessment of upper tract urothelial carcinoma.
Conditions
- Renal Pelvis and Ureter Urothelial Carcinoma
Interventions
Analgesic AgentDrug
Given PO
Electronic Health Record ReviewOther
Ancillary studies
Lidocaine TopicalDrug
Given intraurethrally
Medical Device Usage and EvaluationDevice
Undergo ureteroscopy using 6.3 Fr single use digital ureteroscope
Survey AdministrationOther
Ancillary studies
UreteroscopyProcedure
Undergo ureteroscopy
Primary outcomes
What the sponsor says the trial is designed to measure.
- Success rateTime frame: On day of procedure
Locations
1 site in 1 country. Site status is shown where the registry gives one.
University of Michigan Rogel Cancer Center
Ann Arbor, Michigan · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.